8 completed, 2 withdrawn, 1 unknown. 11 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 11 | Completed 8, Withdrawn 2, Unknown 1 |
Follow Gaucher Disease: new trials by email Literature Review of Gaucher Disease trials Research Report on Gaucher Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy Digital Engagement Application (GD App), No Intervention - Gaucher Disease | Phase 4 | Completed | Takeda | 4 | 2021-04-22 | 2023-12-21 |
| Study to Evaluate Efficacy and Safety of Imiglucerase Treatment in Chinese Patients With Gaucher Disease Type Ⅲ Cerezyme® / Imiglucerase - Gaucher's Disease | Phase 4 | Completed | Sanofi | 12 | 2021-03-02 | 2025-09-15 |
| A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease Elelyso - Gaucher Disease, Type 3 | Phase 4 | Completed | Ari Zimran | 14 | 2020-11-20 | 2024-12-17 |
| Pharmacokinetics, Pharmacodynamics And Safety Study Of Elelyso(tm) In Pediatric Subjects With Type 1 Gaucher Disease Elelyso 60 units/kg - Type 1 Gaucher Disease | Phase 4 | Withdrawn | Pfizer | 2019-07-31 | 2019-09-24 | |
| Chronic Hepatitis C Treatment in Egyptian Children With Gaucher Disease. Ledipasvir/Sofosbuvir - Gaucher Disease, HCV | Phase 4 | Unknown | Mansoura University Children Hospital | 10 | 2018-04-03 | 2018-10-30 |
| Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease Velaglucerase alfa, Vitamin D - Gaucher Disease | Phase 4 | Completed | Shire | 21 | 2016-06-29 | 2022-02-01 |
| Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) VPRIV - Gaucher Disease, Type 1 | Phase 4 | Completed | Shaare Zedek Medical Center | 15 | 2016-01-10 | 2022-10-28 |
| The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease Velaglucerase alfa - Gaucher Disease Type 1, Gaucher Disease Type 3 | Phase 4 | Withdrawn | Baylor Research Institute | 2015-07-01 | 2018-03-02 | |
| A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease Taliglucerase alfa - Gaucher Disease | Phase 4 | Completed | Pfizer | 11 | 2010-08-01 | 2018-10-05 |
| Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease Cerezyme - Gaucher Disease, Type 1, Cerebroside Lipidosis Syndrome | Phase 4 | Completed | Genzyme, a Sanofi Company | 95 | 2001-12-01 | 2015-04-03 |
| A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease. Cerezyme (imiglucerase for injection) - Gaucher Disease Type I, Cerebroside Lipidosis Syndrome | Phase 4 | Completed | Genzyme, a Sanofi Company | 40 | 1997-12-01 | 2015-03-05 |
Brain Diseases (11) · Brain Diseases, Metabolic (11) · Brain Diseases, Metabolic, Inborn (11) · Central Nervous System Diseases (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11) · Genetic Diseases, Inborn (11) · Lipid Metabolism Disorders (11) · Lipid Metabolism, Inborn Errors (11) · Lipidoses (11) · Lysosomal Storage Diseases (11) · Lysosomal Storage Diseases, Nervous System (11) · Metabolic Diseases (11) · Metabolism, Inborn Errors (11) · Nervous System Diseases (11) · Nutritional and Metabolic Diseases (11)
Glucosylceramidase (3) · imiglucerase (3) · taliglucerase alfa (2) · Injections (1) · Vitamin D (1) · ledipasvir, sofosbuvir drug combination (1)
Genzyme, a Sanofi Company (2) · Pfizer (2) · Ari Zimran (1) · Baylor Research Institute (1) · Mansoura University Children Hospital (1) · Sanofi (1) · Shaare Zedek Medical Center (1) · Shire (1) · Takeda (1)
United States (6) · Israel (3) · Spain (2) · United Kingdom (2) · Brazil (1) · Canada (1) · China (1) · Egypt (1) · India (1) · Italy (1) · Paraguay (1) · Poland (1) · South Africa (1) · Turkey (Türkiye) (1)
Ari Zimran (1) · Ari Zimran, Prof. (1) · Edward Kaye, M.D. (1) · Raphael Schiffmann, M.D.,M.H.Sc. (1)
2015 (1)